assay kits on a custom Opentrons Flex® workstation. Scientists and engineers will collaborate to develop and verify platform workflows utilizing the broad offering of automation-enabled assays from the Life Science business of Merck KGaA,...
Syncona Limited, Forbion, Oxford Science Enterprises, TCGX, Advent Life Sciences and additional investors. Find more information please visit, www.beacontx.com.
leading to substantial discontinuation of patients' treatment in less than three months due to intolerable acneiform rashes. LUT014, a novel B-Raf inhibitor, is used for patients who develop dose-limiting rashes, potentially allowing them to...
for cell and gene therapies make them an ideal manufacturing partner and align perfectly with our mission to deliver transformative therapies for cardiovascular diseases and beyond." About Cellipont: Cellipont Bioservices is a premier Contract...
drug administration, announced the introduction of Daikyo PLASCAP® Ready-to-Use Validated (RUV) closures in a new nested format available in multiple configurations at this year's Pharmapack event in Paris, France. This marks West's latest product...
Artax Biopharma, Inc., a clinical-stage biotechnology company focused on transforming the treatment of autoimmune diseases, today announces achievement of clinical validation through its Phase 2a clinical trial in psoriasis with fully proprietary...
technologies in an effort to develop malaria vaccines with MalarVx," said Steve Reed, Ph.D., CEO of HDT Bio. "Our LION platform has a demonstrated ability to rapidly generate potent, durable immune responses with a favorable safety profile." "This...
we elucidated the biomolecular mechanisms underlying PFOS-induced neurobehavioral changes and evaluated the analytical performance of the MTBE-based strategy by comparing it with previous findings of PFOS-induced metabolomic dysregulation." In...
reach the clinical stage and utilises a synthetic promoter designed using Chromatin Bio's proprietary promoter design platform, chromatinLENS, exclusively for EsoBiotec as part of its innovative approach to immunotherapy. EsoBiotec's ESO-T01,...
for sequencing and analyzing proteins in a simple, integrated workflow. Its design prioritizes accessibility, transforming complex protein sequencing into a seamless process for every lab, everywhere. Platinum Pro is Quantum-Si’s newest...
by a mutation in the CYP4V2 gene that causes metabolic enzyme dysfunction wherein yellow-white crystalline lipid deposits form in the retina and cornea, causing the retinal pigment epithelium to degenerate. Resultant symptoms include night...
of Flow Cleanrooms and Supply and Technical Air Products. Today, Modular Devices Cleanrooms serves as a comprehensive platform, offering pre-built cleanrooms for lease or purchase, along with custom modular solutions tailored to highly regulated...
the Company's therapeutics portfolio derived from its novel, proprietary X-E3L (Crosslinking E3 Labeller) technology platform which accelerates the discovery of first-in-class small molecule protein stabilising drugs targeting E3 ligases. Dr...
Nature’s Toolbox (NTx), a life sciences company developing next-generation platforms for RNA and protein manufacturing, announced the full commercial availability of NTxscribe®, a benchtop, continuous flow RNA in vitro transcription (IVT) and...
of Manchester. “Chemify is uniquely positioned to disrupt the industry through its AI, digital chemistry and robotics platform that will not only optimize and expedite the discovery of novel molecules, but accelerate the availability of life-saving...
Board of Directors and Partner, Monograph Capital. "We started Ouro with an intention of building a discovery platform to unlock immune reset therapeutics, and we have been excited to accelerate the company's development by bringing in OM336, which...
In founding his skincare company, Murad, in 1989, Dr. Murad, MD, FAAD, brought to the world his groundbreaking skincare formulas that produce measurable results without cosmetic surgery. His more recent efforts have focused on Modern Wellness,...
In a recent achievement, DP Technology's hit discovery platform RiDYMO® has successfully designed a cyclic peptide targeting β-catenin, a historically "undruggable" protein, in just two months. This innovative AI-driven approach combines advanced...
of certain items in NLS's extraordinary general meeting on January 7, 2025. As previously detailed in NLS's Report on Form 6-K submitted to the Securities and Exchange Commission on December 4, 2024, this agreement involved no warrants and was...
Calcium/Calmodulin-dependent Protein Kinase II (CaMKII) inhibitor for rare and common cardiovascular diseases. For more information, please visit https://cardurion.com.
